Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Adenocarcinoma 1

Interventions

Paclitaxel 27Carboplatin 23Cisplatin 16Topotecan 8Taxes 8Docetaxel 7Gemcitabine 6Filgrastim 5Etoposide 4Doxorubicin 4Cyclophosphamide 4Psychiatric Rehabilitation 3Ifosfamide 3Chemotherapy, Adjuvant 3rubitecan 2pegfilgrastim 2paclitaxel poliglumex 2liposomal doxorubicin 2Trabectedin 2Surgical Procedures, Operative 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Irinotecan 2GEN-1 2Fenretinide 2Erlotinib Hydrochloride 2Drug Therapy 2Celecoxib 2Bevacizumab 2Amifostine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Ovarian Neoplasms × ALK1-Fc fusion protein, human × Clear all
NCT01720173 2021-10-20

Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

GOG Foundation

Phase 2 Completed
30 enrolled 10 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡